Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05749627
NA

Using Neoantigen Peptide Vaccine/neoantigen-based DC to Treat Advanced Malignant Solid Tumors

Sponsor: The First Affiliated Hospital of Nanchang University

View on ClinicalTrials.gov

Summary

In this study, the investigators provide a personalized tumor neoantigen peptide vaccine/neoantigen-based DC treatment to patients with advanced malignant solid tumors. The investigators observe the post-treatment tumor burden status, the immune response induced by immune preparations, and the prolongation of patient survival time, aiming to evaluate the effectiveness and safety of the neoantigen-based DC treatment.

Official title: A Clinical Study of Personalized Tumor Neoantigen Peptide Vaccine/neoantigen-based Dendritic Cells in the Treatment of Advanced Malignant Solid Tumors

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2023-04-01

Completion Date

2025-12-31

Last Updated

2025-02-27

Healthy Volunteers

No

Interventions

DRUG

Neoantigen peptide vaccine

Personalized tumor neoantigen peptide vaccine

DRUG

Neoantigen-based DC immune preparation

Personalized tumor neoantigen DC therapeutic immune preparation

Locations (1)

First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China